The relationships of leptin, adiponectin levels and paraoxonase activity with metabolic and cardiovascular risk factors in females treated with psychiatric drugs

Clinics

Volumn 63, Issue 5, 2008, Pages 651-660

  Ozenoglu, Aliye ^a   Balci, Huriye ^a   Ugurlu, Serdal ^b   Caglar, Erkan ^a   Uzun, Hafize ^a   Sarkis, Cihat ^a   Gunay, Can ^a   Eker, Engin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Adiponectin; Obesity; Paraoxonase; Psychiatric drugs

Indexed keywords

ADIPONECTIN; ADIPONECTIN, HUMAN; ANTIDEPRESSANT AGENT; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; LEPTIN; PON1 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD; BODY MASS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; MENTAL DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; WAIST HIP RATIO;

ADIPONECTIN; ADULT; ANTIDEPRESSIVE AGENTS; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LEPTIN; MENTAL DISORDERS; METABOLIC SYNDROME X; OBESITY; WAIST-HIP RATIO;

EID: 54449101357     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322008000500014     Document Type: Article

References (50)

1. Yamashita S, Nakamura T, Shimomura I, Nishida M, Yoshida S, Kotani K, et al. Insulin resistance and body fat distribution. Diabetes Care. 1996;19:287-91.
2. Gale SM, Castracane VD, Mantzoros CS. Energy homeostasis, obesity and eating disorders: Recent advances in endocrinology. J Nutr. 2004;134:295-8.
3. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat derived hormon adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7:941-6.
4. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S. Et al. Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-95.
5. Heilbronn LK, Smith SR, Ravussin E. The insulin sensitizing role of the fat derived hormone adiponectin. Curr Pharm Design. 2003;9:1411-18.
6. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in man. JAMA. 2004;29:1730-7.
7. Spiegelman BM, Choy L, Hotamisligil GS, Graves RA, Tontonoz P. Regulation of adipocyte gene expression in differantiation and syndromes of obesity/diabetes. J Biol Chem. 1993;268:6823-6.
8. Ouchi N, Kihara S, Funahasti T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol. 2003;14:561-6.
9. Mutlu-Turkoglu U, Oztezcan S, Orhan Y, Aykac-Toker G, Sivas A, Uysal M. An increase in lipoprotein oxidation and endogenous lipid peroxides in serum of obese women. Clin Exp Med. 2003;2:171-74.
10. Myara I, Alamowitch C, Michel O, Heudes D, Bariety C, Guy-Grand B, Chevalier J. Lipoprotein oxidation and plasma vitamin E in nondiabetic normotensive obese patients. Obes Res 2003;11:112-20.
11. Mertens A, Verhamme P, Bielicki JK, Philips MC, Quarck R, Verreth W, Stengel D, Ninio E, Navab M, Macness B, et al. Increased low-density lipoprotein oxidation and impaired high density antioxidant defence are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice. LCAT gene transfer decreases atherosclerosis. Circulation. 2003;107; 1640-46.
12. Durrington PN, Mackness B, Mackness MI. Paraoxanase and aterosclerosis. Arterioscler Tromb Vasc Biol. 2001;2:473-80.
13. Aronne LJ. Epidemiology, morbidity and treatment of overweight and obesity. Journal of Clinical Psychiatry. 2001;62:13-22.
14. Rosmond R, Björntorp P. The role of antidepressants in the treatment of abdominal obesity. Medical Hypotheses. 2000;54:990-94.
15. Özenoǧlu A. Medical nutrition therapy in obesity 2001; 1st Edition, Ýstanbul Dilek Ofset
16. Özenoǧlu A. Approaches to the alteration in appetite and body weight during psychiatric diseases treatment. Science of Diabetes. : 4 (1) 34-50
17. Rosmond R, Björntorp P. Endocrine and metabolic aberrations in men with abdominal obesity in relation to anxio-depressive infirmity. Metabolism. 1998;47:1187-93.
18. Rosmond R, Dalman MF, Björntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesitl and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab. 1998;83:1853-59.
19. Björntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabet Med. 1999;16:373-83.
20. Rosmond R, Björntorp P. Blood pressure in relation to obesity, insulin and the hypothalamic-pituitary-adrenal axis in Swedish men. J Hypertens. 1998;16:1721-26.
21. Melkersson KI, Hulting AI. Insulin and leptin levels in patients with schizophrenia or related psychoses-a comparision between different antipsychotic agents. Psychopharmacology. 2001;154:205-12.
22. Brömel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry. 1998;3:76-80.
23. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kühn M, Uhr M, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry. 1999;156:312-4.
24. Hert MA, Winkel RV, Eyck DV, Hanssens L, Wampers M, Scheen A, Peuskens J. Prevalance of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophrenia Research. 2006;83:87-93.
25. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, et al.Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry. 2001;158:1719-22.
26. Atmaca M, Kulo lu M, Tezcan E, Ustünda B. Weight gain and serum leptin levels in patients on lithium treatment. Neuropsychobiology. 2002;46:67-9.
27. Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmächer T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology (Berl). 2000;149:163-9.
28. Atmaca M, Kuloglu M, Tezcan E, Ustunda B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64:598-604.
29. Kondo H, Shimomura I, Matsukawa Y, Kumada M, Takahashi M, Matsuda M, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes. 2002; 5:2325-8.
30. Im JA, Kim SH, Lee JW, Shim JY, Lee HR, Lee DC. Association between hypoadiponectinemia and cardiovascular risk factors in nonobese healthy adults. Metabolism Clinical and Experimental 2006;55:1546-50.
31. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in man. Arterioscler Thromb Vasc Biol 2003;23:85-9.
32. Ryan AS, Berman DM, Nicklas BJ, Sinha M, Gingerich R, Meneilly GS, et al. Plasma adiponectin and leptin levels, body composition and glucose utilisation in adult women with wide ranges of obesity. Diabetes Care 2003;26:2383-88.
33. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-92.
34. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in man. JAMA. 2004;291:1730-37.
35. Ouchi N, Shibata R, Walsh K. Cardioprotection by adiponectin. Trends Cardiovasc Med. 2006; 16:141-46.
36. Taborsky GJ, Havel PJ, Porte D. Stres-induced activation of the neuroendocrine system and its effects on carbohydrate metabolism. In: Ellenberg & Rifkin's Diabetes Mellitus 1997; Porte D, Sherwin RS (eds). Appletion & Lange 5th ed. USA, 141-51.
37. Brochu M, Poehlman ET, Ades PA. Obesity, body fat distribotion, and corornaty artey disease. J Cardiopulmonary Rehabil 2000; 20: 96-108.
38. Alberti KGMM, Zimmet P, Shaw J. Metabolic Syndrome- a new worldwide definition. A concensus statement from the International Diabetes Federation. Diabetic Medicine. 2006;23:469-80.
39. Özenoǧlu A., Can G, Hatemi H. Body composition reference values of adult women and men grouped as normal weight, overweight, obese and morbidly obese according to the body mass index.
40. Grundy SM, Hansen B, Smith SC, Cleeman CI, Kahn RA. Clinical treatment of the metabolic syndrome. AHA/NHLBI/ADA conrefence report. Circulation. 2004;109:551-56.
41. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.
42. Amamoto T, Kumai T, Nakaya S, Matsumoto N, Tsuziki Y, Kobayashi S. The elucidation of the mechanism of wei ht gain and glucose tolerance abnormalities induced by chlorpromazine. J Pharmacol Sci. 2006;102:213-19.
43. Ferretti G, Baccetti T, Moroni C, Savino S, Liuzzi A, Balzola F, Bicchiega V. Paraoxanase activity in high density lipoproteins: Comparision between healthy and obese females. J Clin Endocrinol Metab. 2005;90:1728-33.
44. Cellini E, Tedde A, Bagnoli S, Nacmias B, Piacentini S, Bessi V, Baracco L, Sorbi S. Association analysis of the paraoxanase-1 gene with Alzheimer's disease. Neuroscience Letters. 2006;408:199-202.
45. Dantoine TF, Debord J, Merle L, Lacroix-Ramiandrisoa H, Bourzeix L, Charmes JP. Paraoxanase I activity: A new vascular marker of dementia? Ann N Y Acad Sci 2002; 977: 96-101.
46. Jaouad L, Milochevitch C, Khahil A. PON 1 paraoxanase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radical Res. 2003; 37:77-83.
47. Ferretti G, Bacchetti C, Marotti E, Carutola G. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxanase activity. Metabolism. 2003;52:146-51.
48. Yamada A, Shoji T, Tahara H, Emoto M, Nishizawa Y. Effect of insulin resistance on serum paraoxanase activity in a nondiabetic population. Metab. 2001;50:805-11.
49. Rosmond R, Björntorp P. The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. J Intern Med. 1999.
50. Groop L, Orho-Melander M. The dysmetabolic syndrom. Journal of Internal Medicine. 2001; 250:105-20.